GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » Cyclically Adjusted Revenue per Share

Genmab AS (STU:GE9) Cyclically Adjusted Revenue per Share : €17.43 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Genmab AS Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab AS's adjusted revenue per share for the three months ended in Sep. 2024 was €11.626. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €17.43 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Genmab AS's average Cyclically Adjusted Revenue Growth Rate was 30.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 35.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab AS was 42.30% per year. The lowest was 32.80% per year. And the median was 36.70% per year.

As of today (2024-12-12), Genmab AS's current stock price is €206.60. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was €17.43. Genmab AS's Cyclically Adjusted PS Ratio of today is 11.85.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 72.33. The lowest was 11.20. And the median was 49.79.


Genmab AS Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted Revenue per Share Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 5.66 7.39 10.96 14.09

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.32 14.09 15.00 16.26 17.43

Competitive Comparison of Genmab AS's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.



Genmab AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=11.626/118.9000*118.9000
=11.626

Current CPI (Sep. 2024) = 118.9000.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.502 99.400 0.600
201503 0.240 100.200 0.285
201506 0.382 100.300 0.453
201509 0.611 100.200 0.725
201512 1.295 99.800 1.543
201603 0.376 100.200 0.446
201606 0.769 100.600 0.909
201609 0.793 100.200 0.941
201612 2.014 100.300 2.387
201703 0.544 101.200 0.639
201706 1.675 101.200 1.968
201709 0.688 101.800 0.804
201712 2.197 101.300 2.579
201803 1.473 101.700 1.722
201806 1.105 102.300 1.284
201809 1.294 102.400 1.503
201812 2.667 102.100 3.106
201903 1.287 102.900 1.487
201906 1.645 102.900 1.901
201909 2.148 102.900 2.482
201912 6.025 102.900 6.962
202003 1.814 103.300 2.088
202006 11.112 103.200 12.802
202009 3.516 103.500 4.039
202012 4.158 103.400 4.781
202103 3.221 104.300 3.672
202106 4.021 105.000 4.553
202109 4.702 105.800 5.284
202112 5.193 106.600 5.792
202203 4.320 109.900 4.674
202206 6.439 113.600 6.739
202209 8.331 116.400 8.510
202212 10.451 115.900 10.722
202303 5.784 117.300 5.863
202306 8.506 116.400 8.689
202309 9.592 117.400 9.715
202312 9.665 116.700 9.847
202403 8.462 118.400 8.498
202406 11.155 118.500 11.193
202409 11.626 118.900 11.626

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Genmab AS  (STU:GE9) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=206.60/17.43
=11.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 72.33. The lowest was 11.20. And the median was 49.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab AS Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » Cyclically Adjusted Revenue per Share
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines